Achieving equitable access to incretin-based therapies in cardiovascular care
The role of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, in the management of type 2 diabetes mellitus (T2DM) and obesity has been increasingly recognized, along with signi...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-10-01
|
Series: | American Heart Journal Plus |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602224000983 |